August 20th 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
ABPI Turned Down for Judicial Review of Budget Impact Test
October 6th 2017The UK's Association of the British Pharmaceutical Industry (ABPI) had hoped to stop a new policy that amounts to price negotiation and potentially delaying access to some new medicines but its request has been denied by the High Court.
Pharm Exec's 16th Annual Industry Audit
September 22nd 2017With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.
The UK's Post-Brexit Life Sciences Strategy: Outlook and Implications
September 5th 2017Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.
Health Policy Problem Solver: Fumie Griego
August 29th 2017Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.
The UK's ‘New’ Statutory Scheme for Pricing of Branded Medicines
August 29th 2017With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the 2014 Pharmaceutical Price Regulation Scheme (PPRS)? Leela Barham reports.
UK Government's New Appointment Offers Inside Track on Pricing and Procurement
July 28th 2017The UK is entering into unchartered waters between Brexit – offering potentially new approaches to procurement – and negotiating a successor to the PPRS. The government's new recruit Steve Oldfield could give it the inside track, writes Leela Barham.